A Comparative Prospective Study to Assess Efficacy of Intralesional MMR (Measles, Mumps, Rubella) Vaccine and Intralesional Vitamin D3 in Treatment of Nongenital Warts
Open Access
- 5 May 2025
- journal article
- research article
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70782
Abstract
Background and Aims: Intralesional immunotherapy is an upcoming method of wart treatment with fewer side effects and this study aims to assess and compare the efficacy of intralesional MMR vaccine and vitamin D3 in the treatment of nongenital warts. Methods: A comparative prospective study was done with a total of 61 patients divided into two groups. Thirty‐one patients were treated with intralesional MMR, while 30 patients received intralesional vitamin D3. In both groups, a maximum of five sessions were carried out every 3 weeks and follow‐up was done for 3 months. χ 2 , Fisher's exact, and multivariate analyses assessed variable relationships. Results: In the MMR group, 80.6% of patients achieved complete response, 6.5% had excellent response, 9.7% showed good response, and 3.2% had no response. Similarly, in the vitamin D3 group, 73.4% achieved complete response, 20.0% had excellent response, 3.3% showed good response and 3.3% had no response. The difference in response rates between the two groups was statistically insignificant. One patient (4.0%) in the MMR group and three patients (13.6%) in the vitamin D3 group experienced recurrence within 3 months of follow‐up, but this difference was not statistically significant. Both treatments were well tolerated. Pain was universal, while swelling (60%), hyperpigmentation (30%), and pruritus (16.7%) were more common with vitamin D3. In logistic regression analysis, pain duration was significantly higher in the Vitamin D group compared to the MMR group ( p < 0.001). Fever (MMR) and hypervitaminosis D3‐related fatigue (vitamin D3) were rare. No severe adverse events occurred. Conclusions: Both intralesional MMR and vitamin D3 showed positive response and were well tolerated and comfortable modalities for the treatment of warts. However, recurrence rate and side effects were higher with Vitamin D3 than MMR. Clinicaltrials.gov : NCT04428359.Keywords
This publication has 26 references indexed in Scilit:
- British Association of Dermatologists' guidelines for the management of cutaneous warts 2014British Journal of Dermatology, 2014
- Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approachInternational Journal of Dermatology, 2014
- Two-year experience of using the measles, mumps and rubella vaccine as intralesional immunotherapy for wartsClinical and Experimental Dermatology, 2014
- Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wartAdvanced Biomedical Research, 2014
- Vitamin D and cancer: a review of molecular mechanismsBiochemical Journal, 2011
- Recalcitrant nongenital warts.2011
- Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccineJournal of the European Academy of Dermatology and Venereology, 2010
- Intralesional Immunotherapy of Warts With Mumps, Candida, and Trichophyton Skin Test AntigensArchives of Dermatology, 2005
- Intralesional tuberculin for treatment of refractory wartsJournal of the European Academy of Dermatology and Venereology, 2005
- The descriptive epidemiology of warts in the communityAustralasian Journal of Dermatology, 1996